Actionable news
All posts from Actionable news
Actionable news in OSIR: Osiris Therapeutics, Inc.,

Here’s Why Brean Capital Downgraded Osiris Therapeutics, Inc. (OSIR) to Sell

In a research report released Tuesday, Brean Capital analyst Jason Wittes downgraded shares of Osiris Therapeutics, Inc. (NASDAQ:OSIR) from a Hold to a Sell rating, while setting a price targt of $8.00, which represents a potential downside of 27% from where the stock is currently trading. Osiris shares reacted to the downgrade, dropping 21.53% to $10.97 on heavy volume, making it among the top losers today.

Wittes explained, “While we have been cautious on the name as a result of elevated DSO’s and extended payment terms, indicating the potential for channel stuffing, the belated release of the recent 10-Q gives us more concern, as it shows evidence of aggressive accounting, particularly in regard to...